**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

An 18-year-old man developed pneumonia caused by COVID-19 during treatment with natalizumab for multiple sclerosis.

The man was diagnosed with multiple sclerosis in 2013. Initially, he received interferon-β-1a \[interferon-β1a\], which was switched to dimethyl-fumarate in 2015 due to lack of efficacy. In October 2019, he started receiving natalizumab \[*route and dosage not stated*\] due to clinical and radiological activity of multiple sclerosis. His neurological examination showed only minimal signs and Expanded Disability Status Scale score was 1.5. At the end of March 2020, his mother showed symptoms of coronavirus disease (COVID-19). He was asymptomatic. Considering the risk of multiple sclerosis rebound following the discontinuation of natalizumab, natalizumab was administered on 30 March 2020. On 2 April 2020, he presented with cough, malaise and fever. Chest x-ray showed bilateral ground glass opacities, consistent with viral pneumonia. Blood test showed a slight elevation in CRP and fibrinogen levels; however, interleukin-6 was found to be low. Reverse transcription-PCR (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) performed on nasopharyngeal swab was found to be negative. Due to a high clinical suspicion of COVID-19 infection, he was initiated on an off-label treatment with azithromycin and hydroxychloroquine. On 3 April 2020, a new RT-PCR for SARS-CoV-2 on nasopharyngeal swab and and serological test (IgM/IgG) were performed and were found to be negative. In view of the typical symptoms and chest x-ray findings, three RT-PCRs for SARS-CoV-2 on nasopharyngeal swab were performed. Only the last sample was found to be positive for SARS-CoV-2 (i.e. fifth sample taken 7 days from the symptoms onset).

The man recovered completely within a week. On 10 April 2020, he was discharged to home-quarantine. Since then, he did not experience any neurological or respiratory symptoms. On 7 May 2020, antibodies against SARS-Cov-2 were found. PCR was again found negative on nasopharyngeal swab. On 11 May 2020 (6 weeks after the previous administration), he received natalizumab according to the extended interval dosing proposed to prevent infectious complications and no infectious complications were noted.
